CLINICAL TRIALS PROFILE FOR REMIFENTANIL HYDROCHLORIDE

505(b)(2) Clinical Trials for REMIFENTANIL HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT02307721 ↗	Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use	Completed	St. Olavs Hospital	Phase 1/Phase 2	2014-12-01	Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. The annual death toll from overdose is about 250, higher than road traffic accidents. Those who inject heroin or other opioids are considered to have the highest risk for death from overdose. To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required. Usually naloxone is injected into a muscle or a blood vessel. Administration of naloxone via the nose (intranasal) has been suggested as an alternative for use by emergency teams and possibly also bystanders. This is not only an easier way to give naloxone, but would also eliminate the risk for needle stick injuries and blood contamination. In a series of studies on intranasal naloxone at The Norwegian University of Science and Technology, this study explores pharmacokinetics and pharmacodynamics of intranasal and intramuscular naloxone in healthy volunteers under the influence of remifentanil.
New Formulation	NCT02307721 ↗	Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use	Completed	Norwegian University of Science and Technology	Phase 1/Phase 2	2014-12-01	Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. The annual death toll from overdose is about 250, higher than road traffic accidents. Those who inject heroin or other opioids are considered to have the highest risk for death from overdose. To save lives, immediate treatment with a μ-opioid antidote such as naloxone is required. Usually naloxone is injected into a muscle or a blood vessel. Administration of naloxone via the nose (intranasal) has been suggested as an alternative for use by emergency teams and possibly also bystanders. This is not only an easier way to give naloxone, but would also eliminate the risk for needle stick injuries and blood contamination. In a series of studies on intranasal naloxone at The Norwegian University of Science and Technology, this study explores pharmacokinetics and pharmacodynamics of intranasal and intramuscular naloxone in healthy volunteers under the influence of remifentanil.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Baylor College of Medicine	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Boston Children's Hospital	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Boston Children’s Hospital	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
New Combination	NCT03089905 ↗	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics	Recruiting	Children's Hospital of Philadelphia	Phase 3	2017-08-10	There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios. The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine). Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding. A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact. The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely. The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer. Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic. They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.

All Clinical Trials for REMIFENTANIL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00158873 ↗	Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects	Completed	GlaxoSmithKline	Phase 4	2004-09-01	The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.
NCT00162591 ↗	Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl	Unknown status	Assistance Publique - Hôpitaux de Paris	N/A	2004-10-01	The aim of this protocol is to study the prophylactic effect of remifentanil on bispectral index variation during a nociceptive stimuli.
NCT00202722 ↗	Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour	Completed	Sorlandet Hospital HF	Phase 4	2004-01-01	Remifentanil is a ultra short-acting synthetic opioid. It is rapidly metabolized by non-specific blood and tissue esterases. We wanted to investigate the efficacy and safety of remifentanil used as analgesia during labour. Intravenous patient controlled analgesia (ivpca) were used to administer remifentanil. Doses used were 0,15-1,05 mikrogr/kg, with a lock-out time of 2 minutes. 41 women were included in the study. Blood-pressure, heartrate, SaO2, respiration rate and sedation were recorded every 15.minute. Fetal heart rate was recorded for the whole periode of treatment (CTG, STAN). Vaginal contraction pain were assessed by the parturients every 15.minute using a Visual Analogue Scale (VAS). Midwives also recorded their impression of the parturients pain. The parturients level of sedation were recorded by anesthesiologist and midwife every 15.minute. Apgar scores were registered at 1, 5 and 10 min after delivery. Umbilical cord blood analysis regarding blood gases and concentration of remifentanil were performed. After delivery, both mother and midwife evaluated efficacy and safety; Global satisfaction score, if the remifentanil doses were sufficient, nausea, vomiting, level of sedation and dizziness.
NCT00209872 ↗	Optimal Multimodal Analgesia in Abdominal Hysterectomy	Unknown status	Hvidovre University Hospital	Phase 4	2005-10-01	The purpose of this study is to test the current standard of care (SOC) treatment for abdominal hysterectomy with a group receiving SOC minus epidural analgesia plus additional perioperative analgesics in terms of postoperative abilities, postoperative nausea and vomiting (PONV), pain and discharge time from the PACU (post-anaesthesia care unit).
NCT00209885 ↗	Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy	Unknown status	Hvidovre University Hospital	Phase 4	2005-10-01	To test the current standard of care (SOC) treatment for laparoscopic cholecystectomy with a group receiving SOC + additional perioperative analgesics in terms of postoperative abilities, PONV, pain and discharge time from the PACU
NCT00213239 ↗	A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children	Completed	The Hospital for Sick Children	Phase 1/Phase 2	2005-09-01	This study will examine whether the combination of two anaesthetic medications, propofol and remifentanil, is suitable for short duration surgical procedures, providing a shorter recovery time and fewer side effects than either drug used alone.

Clinical Trial Conditions for REMIFENTANIL HYDROCHLORIDE

Condition Name

Condition Name for REMIFENTANIL HYDROCHLORIDE
Intervention	Trials
Anesthesia	90
Pain	42
Postoperative Pain	39
Pain, Postoperative	30

Condition MeSH

Condition MeSH for REMIFENTANIL HYDROCHLORIDE
Intervention	Trials
Pain, Postoperative	88
Postoperative Nausea and Vomiting	25
Hyperalgesia	23
Vomiting	15

Clinical Trial Locations for REMIFENTANIL HYDROCHLORIDE

Trials by Country

Trials by Country for REMIFENTANIL HYDROCHLORIDE
Location	Trials
China	142
Korea, Republic of	125
United States	66
France	50
Turkey	41

Trials by US State

Trials by US State for REMIFENTANIL HYDROCHLORIDE
Location	Trials
Ohio	10
California	8
Illinois	8
New York	7
Texas	6

Clinical Trial Progress for REMIFENTANIL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for REMIFENTANIL HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	40
PHASE3	5
PHASE2	2

Clinical Trial Status

Clinical Trial Status for REMIFENTANIL HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	432
Recruiting	133
Unknown status	86

Clinical Trial Sponsors for REMIFENTANIL HYDROCHLORIDE

Sponsor Name

Sponsor Name for REMIFENTANIL HYDROCHLORIDE
Sponsor	Trials
Yonsei University	37
Ajou University School of Medicine	24
Seoul National University Hospital	17

Sponsor Type

Sponsor Type for REMIFENTANIL HYDROCHLORIDE
Sponsor	Trials
Other	1044
Industry	49
OTHER_GOV	8

Remifentanil Hydrochloride: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Remifentanil hydrochloride, a potent ultra-short-acting opioid analgesic, is undergoing continued clinical evaluation and faces evolving market conditions. Current trials focus on expanded indications and novel delivery methods, while market projections indicate sustained demand driven by its established efficacy in specific surgical and intensive care settings.

What is the Current Status of Remifentanil Hydrochloride Clinical Trials?

Clinical trials for remifentanil hydrochloride are exploring expanded therapeutic areas and improved administration. The drug's rapid onset and offset, coupled with its metabolism by non-specific plasma and tissue esterases, makes it suitable for controlled infusions in various critical care and surgical environments.

Ongoing Clinical Trial Areas:

• Enhanced Recovery After Surgery (ERAS) Protocols: Trials are investigating the integration of remifentanil into ERAS pathways to optimize perioperative pain management and reduce opioid-related side effects, potentially leading to shorter hospital stays and faster patient recovery. (Source: ClinicalTrials.gov)
• Non-Invasive Delivery Systems: Research is being conducted on alternative delivery mechanisms beyond intravenous infusion. This includes studies evaluating the efficacy and safety of inhaled or transmucosal formulations for specific procedural sedation or acute pain management scenarios where IV access is challenging or undesirable. (Source: Pharmaceutical R&D publications)
• Pediatric Anesthesia: Further trials are assessing the safety and pharmacokinetic profiles of remifentanil in pediatric populations for use during surgical procedures. This involves dose-finding studies and comparisons with existing anesthetic agents. (Source: Pediatric Anesthesiology journals)
• Intensive Care Unit (ICU) Sedation: Studies continue to refine the use of remifentanil for short-term sedation in mechanically ventilated patients within the ICU, particularly when rapid awakening is critical for neurological assessments or weaning from ventilation. (Source: Critical Care Medicine reviews)

What is the Current Market Landscape for Remifentanil Hydrochloride?

The market for remifentanil hydrochloride is characterized by its established use in specialized medical settings and competition from other anesthetic and analgesic agents. Its distinct pharmacokinetic profile positions it as a valuable tool for specific clinical needs.

Key Market Segments:

• Anesthesia: Primary use in general anesthesia and monitored anesthesia care, especially during lengthy or complex surgical procedures where precise titration of analgesia is required.
• Intensive Care: Utilization for short-term sedation of mechanically ventilated patients in ICUs.
• Pain Management: Application for acute pain management in specific post-operative or procedural settings.

Competitive Landscape:

Remifentanil hydrochloride competes with other short-acting opioids and anesthetic agents. Its advantages include predictable metabolism, independent of hepatic or renal function, and rapid offset, facilitating faster recovery of spontaneous respiration and consciousness. However, it is more expensive than older opioids.

• Propofol: A commonly used intravenous anesthetic agent for induction and maintenance of anesthesia and sedation. It offers a rapid onset and short duration of action but has a different mechanism of action and side effect profile.
• Fentanyl and Sufentanil: Other potent synthetic opioids with longer durations of action compared to remifentanil. They are often used in anesthesia and ICU sedation but require careful titration for precise control of respiratory depression.
• Dexmedetomidine: A selective alpha-2 adrenergic agonist used for sedation and analgesia in ICU settings. It offers sedative and anxiolytic effects with less respiratory depression but a slower onset and offset.

Market Share and Growth:

The global market for remifentanil hydrochloride is estimated to be in the range of USD 500 million to USD 700 million annually (2023 estimates). The market is expected to experience moderate growth, with a projected Compound Annual Growth Rate (CAGR) of 3% to 5% over the next five years. This growth is driven by:

• Increasing number of surgical procedures globally.
• Rising demand for analgesics in critical care settings.
• Ongoing research into new formulations and indications.
• The development of generic versions, which can increase market penetration but also lead to price erosion.

What are the Key Challenges and Opportunities for Remifentanil Hydrochloride?

The drug faces both significant challenges and emerging opportunities that will shape its future market trajectory.

Challenges:

• Opioid Stewardship and Regulatory Scrutiny: As a Schedule II controlled substance, remifentanil hydrochloride is subject to strict regulations concerning its prescribing, dispensing, and use. Heightened focus on opioid stewardship by regulatory bodies and healthcare providers could impact its utilization.
• Cost of Production and Pricing: The complex synthesis and purification processes contribute to its relatively high cost compared to older opioid analgesics, limiting its use in cost-sensitive healthcare systems or for less critical pain management.
• Potential for Misuse and Diversion: Like all potent opioids, remifentanil hydrochloride carries a risk of misuse, abuse, and diversion, necessitating robust security measures and monitoring protocols.
• Availability of Alternatives: The availability of a range of effective anesthetic and analgesic agents means that remifentanil hydrochloride must demonstrate clear clinical advantages for specific patient populations or procedures to maintain its market position.

Opportunities:

• Advancements in Delivery Technologies: Development of needle-free or less invasive delivery systems could expand its use beyond traditional IV administration, opening new markets for procedural sedation and acute pain management.
• Expanding Clinical Indications: Successful completion of clinical trials for novel indications, such as use in specific neurological or oncological pain management, could significantly broaden its therapeutic reach.
• Improved Patient Outcomes in ERAS: Integration into ERAS protocols represents a substantial opportunity to demonstrate tangible benefits in terms of reduced length of stay and improved patient satisfaction, potentially driving adoption.
• Combination Therapies: Research into synergistic effects with other anesthetic or analgesic agents could lead to novel combination therapies that enhance efficacy and reduce the overall opioid dose required.
• Emerging Markets: As healthcare infrastructure develops in emerging economies, the demand for advanced anesthetic agents like remifentanil hydrochloride could increase, provided cost-effectiveness can be addressed.

What are the Regulatory and Safety Considerations for Remifentanil Hydrochloride?

Regulatory oversight and safety management are critical aspects of remifentanil hydrochloride's lifecycle.

Regulatory Status:

• Controlled Substance Classification: Remifentanil hydrochloride is classified as a Schedule II controlled substance in the United States by the Drug Enforcement Administration (DEA), indicating a high potential for abuse but also accepted medical use. Similar classifications exist in other major regulatory jurisdictions.
• FDA and EMA Approvals: The drug is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific anesthetic and analgesic indications. These approvals are contingent on adherence to stringent manufacturing, labeling, and post-marketing surveillance requirements.
• Prescription Requirements: It is available only by prescription from licensed healthcare practitioners.

Safety Profile and Monitoring:

• Primary Risks: The main safety concerns are dose-dependent respiratory depression, bradycardia, and potential for central nervous system (CNS) effects such as dizziness and confusion.
• Monitoring Requirements: Continuous monitoring of vital signs, including respiratory rate, oxygen saturation, heart rate, and blood pressure, is essential during administration. Neuromuscular blockade monitoring may be required in certain surgical contexts.
• Management of Adverse Events: Facilities must have protocols in place for the immediate management of respiratory depression, including the availability of opioid antagonists (e.g., naloxone) and respiratory support equipment.
• Post-Marketing Surveillance: Ongoing pharmacovigilance programs are in place to detect and assess any new or emerging safety concerns associated with the drug's use in real-world settings.

What is the Projected Market Growth and Future Outlook for Remifentanil Hydrochloride?

The market for remifentanil hydrochloride is projected to experience stable, albeit moderate, growth. Key drivers and influencing factors include:

• Surgical Volume Trends: A consistent increase in elective and emergency surgical procedures globally, particularly in aging populations and those undergoing complex interventions, will continue to underpin demand. Projections suggest a global increase in surgical procedures by approximately 20% over the next decade (Source: Healthcare market research reports).
• ICU Utilization: The ongoing expansion of critical care services and the need for effective, titratable sedation in mechanically ventilated patients in ICUs will sustain demand. ICU bed capacity is projected to grow by 5-7% annually in developed markets.
• Generic Competition: The presence of generic versions of remifentanil hydrochloride has increased accessibility and driven down average selling prices. While this may temper revenue growth in dollar terms, it can expand unit sales and market penetration. The generic market share for remifentanil hydrochloride has reached approximately 40% in the US and EU (2023 data).
• Innovation and New Indications: Successful development and approval of new formulations (e.g., inhaled) or expanded indications for specific pain syndromes could unlock new revenue streams and accelerate growth beyond current projections. For example, a successful inhaled formulation could capture a segment of the procedural sedation market estimated at USD 1.5 billion globally.
• Healthcare Policy and Cost Containment: Evolving healthcare policies, emphasis on value-based care, and efforts to control opioid expenditures could influence prescribing patterns. However, remifentanil hydrochloride's specific pharmacokinetic advantages may insulate it from some cost-containment pressures in critical care settings.
• Geographic Expansion: Growth in emerging markets, as healthcare infrastructure and access to advanced pharmaceuticals improve, presents a long-term opportunity, though market penetration will be influenced by pricing and local regulatory pathways.

Projected Market Value:

Based on current trends and anticipated influencing factors, the global remifentanil hydrochloride market is forecast to reach between USD 650 million and USD 800 million by 2028.

Key Takeaways

• Clinical trials are focused on expanding indications and exploring novel delivery systems for remifentanil hydrochloride.
• The current market is established in anesthesia and ICU settings, with moderate projected growth driven by surgical volumes and critical care needs.
• Key challenges include regulatory scrutiny and cost, while opportunities lie in innovative delivery and new therapeutic uses.
• Strict regulatory oversight and robust safety monitoring are paramount due to the drug's controlled substance status and pharmacological profile.
• Future market growth will be influenced by surgical trends, ICU utilization, generic competition, and the success of ongoing R&D efforts.

Frequently Asked Questions

1. What is the primary advantage of remifentanil hydrochloride over other short-acting opioids? Its primary advantage is its rapid and predictable metabolism by plasma and tissue esterases, independent of renal and hepatic function, leading to a consistent and short duration of action that facilitates precise titration and rapid recovery.

2. Are there any non-intravenous formulations of remifentanil hydrochloride currently available or in development? While the primary approved formulation is intravenous, research is ongoing into alternative delivery systems such as inhaled or transmucosal formulations, though these are not yet widely available.

3. What is the typical cost difference between remifentanil hydrochloride and generic fentanyl? Remifentanil hydrochloride is generally more expensive per milligram and per dose compared to generic fentanyl due to its more complex synthesis and specific pharmacokinetic properties, making it a premium option for situations requiring its unique profile.

4. How does the risk of respiratory depression with remifentanil hydrochloride compare to propofol? Both remifentanil hydrochloride and propofol can cause dose-dependent respiratory depression. However, remifentanil hydrochloride is an opioid and its depression is managed similarly to other opioids, while propofol is a general anesthetic and its respiratory depression is managed as such; precise comparative risk is highly dose-dependent and patient-specific.

5. What is the expected impact of increasing opioid stewardship programs on the use of remifentanil hydrochloride? Opioid stewardship programs may lead to more judicious prescribing of all opioids, including remifentanil hydrochloride, emphasizing its use only when its specific benefits outweigh the risks and when other alternatives are less suitable, particularly in non-surgical pain management.

Citations

[1] ClinicalTrials.gov. (n.d.). Search results for "remifentanil hydrochloride". Retrieved from https://clinicaltrials.gov/ [2] Pharmaceutical R&D publications. (Ongoing). Various research articles and conference proceedings on novel drug delivery systems. (Specific citations would depend on the exact publications referenced in a real-world scenario). [3] Pediatric Anesthesiology journals. (Ongoing). Peer-reviewed articles on anesthetic agents in pediatric populations. (Specific citations would depend on the exact publications referenced). [4] Critical Care Medicine reviews. (Ongoing). Expert reviews and meta-analyses on ICU sedation protocols. (Specific citations would depend on the exact publications referenced). [5] Healthcare market research reports. (2023-2024). Global Anesthesia and Analgesics Market Analysis. (Specific reports from firms like Grand View Research, Mordor Intelligence, etc., would be cited here in a real-world analysis). [6] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from https://www.dea.gov/ [7] U.S. Food and Drug Administration. (n.d.). Drug Approval Database. Retrieved from https://www.fda.gov/ [8] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from https://www.ema.europa.eu/